Antibody Research in the COVID-19 Pandemic

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 229

Special Issue Editor


E-Mail Website
Guest Editor
Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD 20993, USA
Interests: vaccines; therapeutics; antibodies; virus; animal models
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

The COVID-19 pandemic shook the world globally with dreadful implications, but also demonstrated an unprecedented collective response to the SARS-CoV-2 infection. To address global public health, this Special Issue will discuss the methods and approaches to illustrate and profile the immune response following infection and vaccination. 

We would like to invite you to share your work on vaccines and/or infection (both COVID-19 and other diseases), with an emphasis on immune response studies. 

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: 

  • The antibody response following vaccination.
  • Immune response following infection.
  • Role of number and dosage of vaccination in immune response.
  • The safety of vaccines.
  • Impact of monovalent vs bivalent vaccines.
  • Circulating and emerging SARS-CoV-2 variants. 

We look forward to receiving your contributions. 

Dr. Surender Khurana
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immune response
  • dosage of vaccination
  • SARS-CoV-2 variants

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop